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bstract
The majority of people with type 2 diabetes mellitus (T2DM) require insulin therapy to maintain HbA1c levels < 7% during the first decade
f diagnosis. Large prospective trials investigating the cardiovascular (CV) benefits of intensive glycaemic control have produced inconsistent
esults; however, meta-analyses have suggested that intensive glycaemic control provides both micro- and macrovascular benefits. The ORIGIN
tudy investigated the impact of basal insulin glargine therapy targeting ≤  5.3 mmol/L for fasting plasma glucose compared with standard care
n CV outcomes in people with pre- or early diabetes, and demonstrated a neutral effect on CV outcomes with long-term use of insulin glargine
arly in the course of diabetes, with a low rate of severe hypoglycaemia and modest weight gain. The EARLY, GLORY and EASIE studies also
emonstrated that insulin use earlier in the treatment pathway led to improved glycaemic control, reduced weight gain and fewer hypoglycaemic
pisodes than when insulin was added later in the course of disease. The beneficial effect of early transient intensive insulin therapy (TIIT) at
iagnosis has been demonstrated in a number of trials; it rapidly limits the damage caused by gluco- and lipotoxicity, improving residual -cell
unction and potentially slowing disease progression. The evidence suggests that people newly diagnosed with T2DM and HbA1c > 9% should be
iven early TIIT to achieve normoglycaemia within weeks, after which standard care should then be adopted. Insulin use earlier in the treatment
athway should be considered, as it reduces the risk of hypoglycaemia as well as allows -cell rest, which can help preserve -cell function.
 2014 Elsevier Masson SAS. All rights reserved.
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.  Introduction
Since the development of insulin therapy in the early 20th
entury, insulin has been a key component of diabetes man-
gement, with the majority of people with type 2 diabetes
ellitus (T2DM) requiring insulin therapy to maintain HbA1c
evels < 7% within nine years of diagnosis [1,2]. This glycaemic
arget (HbA1c < 7%) is recommended by the American Diabetes
ssociation (ADA) and European Association for the Study of
iabetes (EASD) in their consensus statement on the manage-
ent of hyperglycaemia, which also emphasizes the need for patient-centred approach to diabetes management [3]. The
anagement strategy outlined by these guidelines reduces the
ncidence of microvascular disease, but does not reduce the risk
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f macrovascular disease to the same extent [4,5]. Therefore,
t present a key unmet need for patients with T2DM is the
revention of cardiovascular (CV) disease, the major cause of
ortality in those with T2DM, with the risk of heart disease-
elated death being two to four times higher in people with
iabetes [6]. Indeed, T2DM is a CV risk factor comparable to
revious myocardial infarction (MI) in people without diabetes
ged 30 years or older [7].
T2DM develops over a number of years, with changes in glu-
ose levels, insulin sensitivity and insulin secretion happening
–6 years before diagnosis and a deficit in -cell capacity up
o 12 years before diagnosis [8–10]. Initial insulin resistance is
ccompanied by a deficit in early-phase insulin secretion as a
esult of loss of -cell mass [11–14]. This results in mild hyper-
lycaemia, which is termed ‘impaired glucose tolerance’ (IGT)
15], and defined as fasting plasma glucose (FPG) < 7.0 mmol/L
nd postprandial plasma glucose (PPG) 7.8–11.1 mmol/L fol-
owing a 75-g oral glucose challenge [15]. When people are
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dentified as having IGT, they can be treated with diet, exercise
nd drugs to reduce their mild hyperglycaemia, which reduces
onversion to T2DM [16]. As glucose levels rise, glucotoxicity
urther damages   cells, while increased free fatty acid levels
uring IGT also damage   cells (lipotoxicity) [17]. At some
oint, gluco- and lipotoxicity will damage   cells to the extent
hat the production of insulin becomes inadequate, resulting in
 relatively rapid rise of blood glucose levels and the develop-
ent of T2DM [11]. Nevertheless, endogenous insulin may still
e produced by the remaining -cells, and blood glucose lev-
ls may be stabilized at much higher levels, with the remaining
-cell mass becoming damaged more slowly [11]. This slow
amage results in the progressive nature of T2DM, and stud-
es have suggested that achieving glycaemic targets early in the
isease course can improve outcomes, including CV outcomes,
wing to less damage from hyperglycaemia [4,5].
The present review is an overview of recent large clinical
rials, including the Action to Control Cardiovascular Risk in
iabetes (ACCORD) trial [18], Action in Diabetes and Vascular
isease: Preterax and Diamicron Modified-Release Controlled
valuation (ADVANCE), [19] the Veterans Affairs Diabetes
rial (VADT) [20,21] and the Outcome Reduction with an Initial
largine Intervention (ORIGIN) study, as well as other smaller
rials (including EASIE, EARLY and GLORY). Here the partic-
lar focus is on the earlier use of insulin as first-line treatment
nd as part of early transient intensive insulin therapy (TIIT) for
he treatment of T2DM. The potential impact of these studies
n clinical practice to improve the management of the disease
s also discussed.
.  Impact  of  glycaemic  control  on  CV  risk  factors
Diabetes is an independent risk factor for CV disease, and
 positive correlation has been demonstrated between the risk
f CV disease and level of glycaemic control [7,22,23]. Several
arge prospective trials – the Diabetes Intervention Study (DIS)
24], United Kingdom Prospective Diabetes Study (UKPDS)
4,25], ACCORD [18], ADVANCE [19] and VADT [20,21] –
ave investigated whether intensive glycaemic control can help
o reduce CV risk in people with T2DM.
Even though the results of the individual trials were incon-
istent, a meta-analysis of UKPDS, ACCORD, ADVANCE and
ADT by Turnbull et al. [26] found that allocation to more-
ntensive glycaemic control reduced the risk of major CV events
y 9% compared with less-intensive glycaemic control (Fig. 1).
his reduction in the risk of major CV events was primarily the
esult of a 15% reduced risk for MI [26]. There was no differ-
nce in mortality between the more and less intensively treated
roups [26]. Findings from meta-analyses of other trials where
ifferences in glycaemic control have been observed also con-
luded that intensive glycaemic control provides macrovascular
enefits [27–29]. It is, therefore, essential to determine which
eople are likely to experience the best outcomes from intensive
ontrol [26–29].
A substudy of the UKPDS investigated the -cell function of
hose treated with either sulphonylurea, diet or metformin dur-
ng the UKPDS [8]. It found that even though -cell function
i
i
i
wolism 40 (2014) 391–399
ontinued to decline despite intervention – with similar declines
een with diet and sulphonylurea treatment after one year – an
ncrease in -cell function was seen with intensive therapy with
ulphonylurea during the first year (Fig. 2) [8,30]. This meant
hat, after 6 years of treatment, there was a greater degree of -
ell function remaining in the intensive-treatment group [8]. This
reater degree of -cell function indicates that more endoge-
ous insulin is being produced, which helps to limit glycaemic
xcursions, thereby reducing damage from hyperglycaemia and
otentially reducing the risk of hypoglycaemia as well.
.  The  ORIGIN  study  and  impact  of  early  insulin
reatment
The early use of therapy targeting FPG ≤  5.3 mmol/L, to
educe the risk of conversion from IGT to T2DM as well as
o lower the risk of longer-term complications, was investigated
n the ORIGIN study [31]. This study investigated the impact
f basal insulin glargine therapy targeting FPG ≤  5.3 mmol/L
ompared with standard care on CV outcomes in 12,537 people
ith CV risk factors and impaired fasting glucose (IFG), IGT
r T2DM [31]. Compared with the ACCORD, ADVANCE and
ADT, the ORIGIN study enrolled people with a shorter mean
uration of T2DM and lower mean baseline HbA1c levels [31].
he early use of basal insulin maintained HbA1c at < 6.5% over
he 6.2 years of the trial, which was achieved with a stable dose of
nsulin glargine, while adherence remained high throughout the
tudy [31]. The dose of insulin glargine remained low through-
ut the study, with the median dose increasing from 0.31 U/kg
t year 1 to 0.40 U/kg at year 6 [31]. During the study, the rate of
V outcomes was similar with both insulin therapy and standard
are [31].
At the start of the ORIGIN study, 11.7% of people in the
nsulin glargine group and 11.4% of those in the standard-care
roup had either IGT or IFG [31]. Such people who were receiv-
ng insulin glargine were 20% less likely to develop T2DM after
.2 years than those receiving standard care [31]. One possible
xplanation for this reduced risk of progression is that the group
eceiving insulin glargine had lower HbA1c levels throughout the
rial; thus demonstrating the importance of optimal glycaemic
ontrol early in the course of disease [31]. In addition, people
eceiving insulin glargine typically required fewer additional
ntidiabetic agents at the end of the study than those receiv-
ng standard care, with 35.1% requiring no oral antidiabetic
rugs (OADs) compared with 19.2% among those receiving
tandard care [31]. Overall, the ORIGIN study demonstrated
hat long-term use of insulin glargine is safe, with a low risk
f severe hypoglycaemia and only moderate weight gain, as
ell as a reduced need for additional OADs or complex insulin
egimens. The relationship between frequency of episodes of
ypoglycaemia and CV outcomes is shown in Table 1 [32].
The Glucose Reduction and Atherosclerosis Continuing
valuation (GRACE) [33] substudy of ORIGIN evaluated thempact of insulin glargine treatment during ORIGIN on carotid
ntima-media thickness (CIMT) [33]. Intima-media thickness
s a measurement of the innermost two layers of the arterial
all, and the CIMT is a surrogate endpoint for atherosclerosis
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Fig. 1. Probabilities of (A) major cardiovascular events, (B) myocardial infarction and (C) all-cause mortality with intensive glucose-lowering vs. standard treatment
[ e 95%
( c = me
U
a
s
a
O
a
w
[
a
d
s
b
f
i
t
c
i
t
s
a
o
d
d26]. The diamond incorporates the point estimate (vertical dashed line) and th
HR) are provided for more-intensive vs. less-intensive glucose control. HbA1
KPDS follow-up truncated at 5 years from randomization.
nd associated CV disease [34,35]. The ORIGIN–GRACE sub-
tudy included 1184 people who underwent carotid ultrasound
t baseline and then yearly until 1–1.3 years prior to the final
RIGIN study visit [33]. Over a median duration of 4.9 years,
 statistically non-significant reduction in CIMT progression
as observed with insulin glargine compared with standard care
33]. The authors highlight that this modest decrease in carotid
therosclerosis is consistent with what was observed in the Epi-
emiology of Diabetes Interventions and Complications (EDIC)
tudy/Diabetes Control and Complications Trial (DCCT), where
enefits were observed after long-term follow-up [33]. However,
urther follow-up is needed to determine whether the decrease
n CIMT observed in the GRACE substudy persists and whether
f
w
u confidence interval (CI) of the overall effect for each outcome. Hazard ratios
an HbA1c of more-intensive group minus mean HbA1c of less-intensive group.
his difference leads to a clinically significant impact on CV out-
omes. Monnier et al. [36] examined the relationship between
nsulin and atherosclerosis, and concluded that early insulin ini-
iation may have a protective function. However, while further
tudy is needed to determine the relationship between insulin
nd atherosclerosis, the authors acknowledge that smaller doses
f insulin earlier on in the disease course are preferable to higher
oses later on.
Overall, the ORIGIN study demonstrated that, in people with
ysglycaemia and CV risk factors, insulin is safe and effective
or controlling blood glucose levels, even though no CV benefits
ere observed. This might have been because long-term follow-
p is required to observe macrovascular benefits; it is hoped
394 M. Hanefeld / Diabetes & Metabolism 40 (2014) 391–399
Table 1
Adjusted propensity scores for the relationship between frequency of hypoglycaemic episodes and cardiovascular (CV) outcomes.
Composite Death CV death Arrhythmia death
Non-severe hypoglycaemia
1 or more episodes 0.51 (0.45–0.57)a 0.64 (0.57–0.71)a 0.57 (0.49–0.66)a 0.57 (0.47–0.71)a
2 or more episodes 0.44 (0.38–0.51)a 0.62 (0.54–0.71)a 0.54 (0.45–0.65)a 0.54 (0.41–0.69)a
3 or more episodes 0.47 (0.40–0.56)a 0.66 (0.57–0.78)a 0.60 (0.49–0.74)a 0.61 (0.46–0.81)a
4 or more episodes 0.48 (0.39–0.58)a 0.66 (0.55–0.79)a 0.63 (0.50–0.80)a 0.63 (0.46–0.87)c
5 or more episodes 0.50 (0.40–0.62)a 0.64 (0.53–0.79)a 0.67 (0.52–0.86)c 0.72 (0.51–1.01)
Severe hypoglycaemia
1 or more episodes 0.79 (0.62–1.00)b 0.93 (0.74–1.16) 0.89 (0.67–1.19) 0.92 (0.62–1.37)
2 or more episodes 0.77 (0.44–1.33) 1.13 (0.74–1.75) 1.05 (0.59–1.85) 1.56 (0.80–3.03)
3 or more episodes 1.16 (0.48–2.79) 1.05 (0.44–2.54) 1.37 (0.51–3.68) 2.65 (0.99–7.12)
4 or more episodes 1.24 (0.31–4.98) 1.96 (0.63–6.08) 2.08 (0.52–8.36) 3.83 (0.95–15.4)
5 or more episodes 1.30 (0.18–9.21) 2.88 (0.72–11.5) 2.21 (0.31–15.8) 3.94 (0.55–28.1)
a P < 0.001.
b P < 0.05.
c P < 0.01
Fig. 2. Impact of intensive therapy with sulphonylurea compared with con-
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tentional therapy using metformin or diet on -cell function, as measured by
omoeostasis model assessment (HOMA) in the United Kingdom Prospective
iabetes Study (UKPDS) [8,30]. * -cell function measured by HOMA.
hat the ORIGIN and Legacy Effects (ORIGINALE) study (a
ong-term follow-up of the ORIGIN trial) will provide further
nformation on this [37]. It is, nevertheless, possible that early
nsulin treatment provides non-CV benefits, including preserva-
ion of -cell function with lower doses of insulin than would
e required later in the disease course, resulting in a lower risk
f hypoglycaemia and only moderate weight gain. This should
nable longer-term treatment that is less complicated, safer and
heaper. These aspects of early insulin treatment have already
een investigated in a number of prospective clinical trials.
.  Studies  investigating  early  insulin  for
on-cardiovascular  beneﬁts
The EARLY study investigated the use of basal insulin as
econd-line therapy following failure of metformin in 1438
eople with T2DM [38,39], and demonstrated that early basal
nsulin therapy was safe and effective, with HbA1c levels
ecreasing from 8.69% to 7.39% and a low rate of hypogly-
aemia over 24 weeks. Subgroup analyses found that people
ith lower HbA1c levels at baseline, lower body mass index
BMI) and/or shorter duration of T2DM were more likely to
chieve glycaemic targets (HbA1c < 7%) [39]. The GLORY
tudy investigated the use of either metformin or insulin glargine
l
b
ts first-line treatment in 75 people with drug-naïve T2DM over
6 weeks [40]. Insulin glargine treatment was associated with
mprovements in FPG, overall interstitial glucose load and -
ell function, with no increased risk of hypoglycaemia compared
ith metformin treatment [40]. However, improvements in PPG
nd endothelial function were similar with insulin glargine com-
ared with metformin [40]. This suggests that if -cell function
s of interest, then insulin glargine might be the best first-
ine treatment; however, in terms of overall effects, including
icrovascular effects, this trial failed to provide enough evi-
ence to suggest changes in clinical practice.
The evaluation of insulin glargine versus sitagliptin in insulin-
aive patients (EASIE) trial compared 24 weeks of treatment
ith either insulin glargine or sitagliptin as add-on treatment
n 515 people with T2DM who had not achieved glycaemic tar-
ets with metformin monotherapy [41]. Insulin glargine reduced
bA1c to a greater extent than sitagliptin (–1.72% vs.–1.13%,
espectively) and with a low rate of hypoglycaemia; thereby
emonstrating that insulin glargine, as a second-line therapy
ollowing metformin failure, may be a good and effective clin-
cal option [41]. Alvarsson et al. [42] compared early use of
ither insulin or sulphonylurea in 49 people with drug-naïve
2DM over six years and found that good glycaemic control
as maintained in both treatment groups; however, -cell func-
ion was preserved to a greater extent in those treated with early
nsulin therapy [42]. The authors suggested that the beneficial
ffect of insulin was a result of -cell rest [42]. This occurs
hen the provision of exogenous insulin reduces the amount
f endogenous insulin the body requires, thus decreasing -
ell stress and reducing the likelihood that they will undergo
poptosis [43]. The use of insulin rather than insulin secretago-
ues is also likely to provide greater -cell rest as the provision
f exogenous insulin reduces the amount of insulin these cells
eed to secrete; whereas, the use of sulphonylureas encourages
ndogenous insulin secretion, further stressing  cells.
A meta-analysis of prospective clinical trials investigating
he addition of insulin glargine to either metformin or sulphony-
urea, or both, in people with uncontrolled T2DM was performed
y Fonseca et al. [44] and included 2171 participants from 11
rials. This meta-analysis found that the addition of insulin to
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etformin monotherapy was more effective than adding it to
herapy with sulphonylurea, resulting in less weight gain and
reater mean HbA1c reduction [44]. Overall, hypoglycaemia
ates were low with the addition of insulin glargine, with higher
ates of hypoglycaemia when insulin was used in combina-
ion with sulphonylurea; thus demonstrating the efficacy and
afety of adding insulin therapy as a second-line therapy after
etformin monotherapy [44].
The BEGIN Once Long study examined the efficacy and
afety of ultra-long-acting insulin degludec compared with
nsulin glargine in 1030 insulin-naïve people with T2DM uncon-
rolled by OADs [45]. People were randomized 3:1 to receive
nsulin degludec and insulin glargine daily with metformin.
eductions in HbA1c were similar with insulin glargine and
nsulin degludec (1.06% vs.  1.19%, respectively) [45]. The study
oncluded that insulin degludec and insulin glargine adminis-
ered once daily in combination with OADs provide good and
imilar glycaemic control, with lower rates of nocturnal hypo-
lycaemia observed with insulin degludec [45]. However, some
otential CV safety concerns are associated with the use of
nsulin degludec [46]. Findings from a meta-analysis of phase-
II trials indicate that insulin degludec may increase the risk of
V death, non-fatal MI, non-fatal stroke and unstable angina by
0% compared with study comparators [46]. As a consequence,
he CV safety of insulin degludec is currently under review by
he US Food and Drug Administration [46].
Meneghini et al. [47] investigated the use of insulin detemir
nd insulin glargine as an add-on to metformin in a randomized
rial of 457 insulin-naïve patients with T2DM over 26 weeks.
ean reductions in HbA1c were similar for insulin detemir
nd insulin glargine (0.48% and 0.74%, respectively). Thus,
lthough glycaemic control was achieved with both insulins,
he proportion of patients at the study endpoint achieving
bA1c ≤  7% was higher with insulin glargine than with insulin
etemir (53% vs.  38%, respectively) [47].
These studies all demonstrate that the use of insulin earlier in
he treatment paradigm as either a first- or second-line therapy is
ffective and well tolerated; however, they do not indicate that
linical practice should be modified to include insulin as the
rst-line therapy of choice for T2DM.
.  Early  transient  intensive  insulin  therapy
A number of studies have investigated the impact of TIIT
o prompt normoglycaemia in people with poorly controlled
2DM [3]. Continuous subcutaneous insulin infusion (CSII),
ultiple daily insulin injections (MDIs) and basal insulin
onotherapy are all effective methods for TIIT in people with
oorly controlled T2DM [48,49]. The impact of TIIT on gly-
aemic outcomes is shown in Table 2 [48–55]. The rapid
cquisition of glycaemic control with TIIT has been found to
nable many people to maintain normoglycaemia following ces-
ation of insulin therapy, using lifestyle management alone for
xtended periods of time (Table 2). This highlights the effective-
ess of TIIT, and is consistent with the ADA/EASD consensus
tatement suggesting that people with moderate hyperglycaemia
hould be started on an antihyperglycaemic agent at diagnosis
c
t
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3]. A meta-analysis of studies investigating TIIT, including 839
articipants from seven studies, found that 66.2% were in drug-
ree remission 3 months after TIIT, which decreased to 42.1% at
4 months [56]. This meta-analysis also compared the character-
stics of people achieving remission with those who did not, and
ound that people with higher BMI or lower FPG at baseline were
ore likely to achieve remission [56]. Other studies have also
nvestigated the characteristics of those who achieved drug-free
emission. Xu et al. [54] found that people in remission for two
ears had significantly better acute insulin responses than those
ot in remission, and the main predictor of remission was the
ime between diagnosis and the two weeks of TIIT used in this
rial (1.00 vs.  4.38 months in the remission and non-remission
roups, respectively). This highlights the rapid decline of -cell
unction in people with T2DM and the need for good glycaemic
ontrol early in the disease course.
.1.  Impact  of  early  TIIT  on  β-cell  function
The rapid acquisition of glycaemic control has been demon-
trated to have a beneficial impact on -cell function in a number
f other studies, with people achieving glycaemic targets with
IIT also having improved -cell function [49,51,54,55]; this
as been confirmed by meta-analysis [56]. Li et al. [51] found
hat the people who experienced the greatest improvements in -
ell function were able to maintain normoglycaemia for longer
ith lifestyle management alone. It is likely that -cell func-
ion would have deteriorated further in those who took longer to
each normoglycaemia and, thus, would result in a lower base-
ine level of -cell function and a poorer prognosis. The impact
f glycaemic control on -cell function was also demonstrated
n a study by Chen et al. [57], which compared 6 months of
reatment with either insulin or OADs in 50 people with newly
iagnosed T2DM and severe hyperglycaemia at diagnosis who
ad been treated with TIIT for 10–14 days to rapidly obtain
lycaemic control. After six months, HbA1c levels were signif-
cantly lower in the insulin-treated group compared with those
eceiving OADs (6.33% vs.  7.50%, respectively; P  = 0.002) [57].
-cell function improved from baseline in both groups; however,
ignificantly greater improvements were seen with insulin ther-
py compared with OADs, most likely as a consequence of the
ower HbA1c levels observed with insulin throughout the study
57]. The improved -cell function seen in these studies might
e the result of -cell rest as a result of insulin therapy, as well
s reduced -cell stress owing to reduced hyperglycaemia.
.2.  Impact  of  early  TIIT  on  low-grade  inﬂammation  and
ndothelial function
The effect of TIIT on the vasculature has also been explored,
ith a number of mechanistic studies describing beneficial
ffects on the vasculature. Chen et al. [53] investigated whether
IIT affected serum tumour necrosis factor (TNF)-, which
auses an inflammatory response and is related to insulin resis-
ance. Their study of 138 people with newly diagnosed T2DM
ound that TNF-  levels were significantly increased by T2DM,
nd that TIIT reduced FPG as well as increased -cell function
396
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Table 2
Effects of intensive insulin therapy (IIT) at time of diagnosis on glycaemic control (GC).
Treatment n  Baseline
HbA1c (%)
HbA1c after
IIT (%)
Baseline
FPG
(mmol/L)
FPG after
IIT
(mmol/L)
Baseline
PPG
(mmol/L)
PPG after
IIT
Days to
achieve GC
Duration
of IIT
% in GC
(duration in
months)a
Ilkova et al. (1997) [50] CSII 13 11.0 ± 0.7 6.1 ± 0.5 12.1 ± 1.1 6.6 ± 0.4 16.9 ± 1.8 7.4 ± 0.4 1.9 ± 0.8 2 weeks 69 (26)b
Li et al. (2004) [51] CSII 126 10.0 ± 2.2 8.7 ± 1.9 13.3 ± 4.4 6.3 ± 1.3 18.7 ± 6.1 8.6 ± 2.3 6.3 ± 3.9 2 weeks 42.3 (24)
Ryan et al. (2004) [52] MDI 16 11.8 ± 0.3 N/A 13.3 ± 0.7 7.0 ± 0.4 N/A N/A N/A 2–3 weeks 44 (12)
Chen et al. (2007) [53] CSII 138 11.9 ± 2.0 N/A 14.62 ± 1.68 6.62 ± 0.54 24.67 ± 8.03 N/A 3.15 ± 1.99 N/A N/A
Weng et al. (2008) [49] CSII 133 9.8 ± 2.3 8.0 ± 1.5 11.3 ± 3.3 6.6 ± 1.5 16.1 ± 5.5 7.5 ± 2.2 4.0 ± 2.5 N/A 51.1 (12)
MDI 118 9.7 ± 2.3 8.0 ± 1.6 11.5 ± 3.2 6.8 ± 1.6 17.5 ± 5.5 8.1 ± 2.9 5.6 ± 3.8 N/A 44.9 (12)
Xu et al. (2009) [54] CSII 84 9.91 ± 2.16 8.69 ± 1.78 13.73 ± 4.57 6.26 ± 1.16 19.36 ± 5.77 8.86 ± 2.49 N/A 2 weeks 50 (24)
Chon et al. (2010) [55] MDI 61 10.7 ± 1.8 6.2 ± 1.1 11.8 ± 3.1 N/A 21.5 ± 4.1 N/A 2.6 months N/A 8.7 (48)
Zeng et al. (2012) [48] CSII 32 10.93 ± 2.23 10.03 ± 1.91 12.47 ± 3.70 5.89 ± 1.22 N/A 6.2 ± 0.9 3.8 ± 1.9 2 weeks N/A
BIM 27 10.78 ± 2.57 9.91 ± 1.95 13.27 ± 3.80 5.66 ± 1.09 N/A 10.2 ± 2.7 5.4 ± 1.4 2 weeks N/A
GC: normoglycaemia without use of antiglycaemic therapy; FPG: fasting plasma glucose; PPG: postprandial glucose; CSII: continuous subcutaneous insulin infusion; MDI: multiple daily insulin injection; BIM:
basal insulin monotherapy.
a Glycaemic remission is defined by normoglycaemia without use of antiglycaemic therapies.
b Median.
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nd decreased TNF-  levels [53]. The authors suggest that the
ecrease in the TNF-  inflammatory marker might be related to
mproved -cell function [53]. Li et al. [58] compared the effect
f either TIIT (prandial insulin thrice daily and intermediate-
cting insulin before bedtime, targeting FPG 4.0–6.1 mmol/L
nd 2-h PPG 5.0–7.8 mmol/L) or conventional insulin treatment
premixed insulin twice daily, targeting FPG 6.0–8.0 mmol/L
nd 2-h PPG 9.0–11.1 mmol/L) on serum adiponectin and
ndothelial function in 42 people newly diagnosed with T2DM;
reatment was maintained for two weeks after glycaemic targets
ad been achieved. Intensive insulin therapy was observed to
ncrease serum adiponectin and nitric oxide concentrations, and
o improve endothelial function to a greater extent than con-
entional insulin therapy [58]. Tian et al. [59] compared the
ffect of treatment with either OADs plus antihypertensive and
ipid-lowering medication or TIIT for two weeks on endothelial
njury/dysfunction in 116 people with newly diagnosed T2DM.
hey found that, compared with the multiple treatment, TIIT sig-
ificantly improved endothelial injury/dysfunction [59]. These
tudies demonstrate that rapidly controlling hyperglycaemia has
eneficial effects on the vasculature. Such effects and the impact
f TIIT on -cell function might explain the beneficial long-term
utcomes seen in clinical trials of early insulin use, including the
mproved microvascular and macrovascular outcomes observed
n the UKPDS [4,5].
.3.  Early  TIIT  in  clinical  practice
Studies of TIIT suggest that a more proactive approach to the
anagement of early dysglycaemia can lead to long-term bene-
ts. A treatment pathway involving initial TIIT to rapidly obtain
lycaemic control, followed by withdrawal of insulin and initia-
ion of OADs according to a patient-centred treatment approach,
s likely to provide improved outcomes in people with T2DM.
owever, it should be noted that intensive glycaemic control is
ot suitable for everyone with T2DM, and such care needs to be
ersonalized. For example, in frail people with poor glycaemic
ontrol, less intensive HbA1c control should be applied, as this
ill reduce the risk of hypoglycaemic episodes, which can have
atastrophic consequences in such a population [3].
.  Conclusion
Long-term prospective studies investigating the effect of
ntensive glycaemic control on CV outcomes have produced
ontradictory results. However, meta-analyses including these
rials suggest that intensive glycaemic control reduces the risk
f CV outcomes without increasing the risk of mortality. Sub-
nalyses of these long-term prospective studies suggest that
ntensive control is beneficial only for some people, which
as led to clinical guidance recommending personalized care
or patients with T2DM. This means that glycaemic targets,
s well as the therapies used, should be chosen based on the
haracteristics of the given individual, with elderly and frail
eople having less stringent glycaemic targets. The ORIGIN
tudy demonstrated that insulin therapy does not increase the
isk of complications in people with T2DM and CV risk factors
R
A
Molism 40 (2014) 391–399 397
ompared with standard care; thus confirming that it is safe to use
n this population. Moreover, in the ORIGIN study, early insulin
herapy targeting HbA1c < 6.5% reduced the risk of people with
GT progressing to T2DM, with a low risk of hypoglycaemia,
nly moderate weight gain and doses of insulin glargine con-
istent with those typically required during phase-III studies of
2DM. There is now a mass of evidence from clinical trials
nd long-term outcome studies that early introduction of basal
nsulin is effective at keeping glucose levels within the target
ange with doses < 0.4 U/kg, which are associated with a low risk
f severe hypoglycaemia and only moderate, if any, weight gain
8,31,39]. In contrast, late basal insulin introduction requires
 high dose of insulin glargine with excessive weight gain
bserved as an adverse effect [60]. The same applies for the intro-
uction of basal insulin after maximum-dose sulphonylurea, and
ual and triple oral combinations with sulphonylurea and/or
ipeptidyl peptidase (DPP)-IV inhibitors [61]. The best evi-
ence supports early insulin use in combination with metformin
s an antihyperglycaemic drug and other recently introduced
ombinations with glucagon-like peptide (GLP)-1 analogues
nd sodium–glucose cotransporter (SGLT)-2 inhibitors [62–64].
n addition, the ORIGIN–GRACE substudy demonstrated a
ecrease in the progression of CIMT with insulin glargine ther-
py that might explain the CV benefits seen in some of the
arlier trials; however, long-term follow-up is needed to con-
rm whether this effect produces clinically relevant differences
etween groups.
While the use of insulin as a long-term therapy has not
een shown to provide clinical benefits beyond glycaemic con-
rol, early TIIT has been found effective for rapidly achieving
lycaemic targets and enabling long-term maintenance of nor-
oglycaemia with lifestyle management alone in about 50% of
eople with newly diagnosed T2DM and hyperglycaemia. TIIT
lso preserves -cell function possibly by reducing glucotoxicity
nd lipotoxicity through strict glycaemic control, which enables
ecovery of residual -cell function. This preserves glucose
omoeostasis, reducing the need for complex treatment regi-
ens and lowering the risk of long-term complications even if
ontrol deteriorates, possibly through metabolic memory. Thus,
eople newly diagnosed with T2DM and HbA1c > 9% should
e given TIIT to rapidly obtain normoglycaemia before mov-
ng them onto standard care, with different glycaemic targets
ased on their given clinical characteristics. In addition, the
arlier use of insulin in the treatment paradigm as second-line
herapy is recommended, as this reduces the risk of hypogly-
aemia following the addition of insulin compared with the
ater addition of insulin, as well as enabling further -cell
est, which preserves -cell function for the longest possible
ime.
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